Don’t wait
Subtle symptoms could be signs of disease progression
Don’t wait
Subtle symptoms could be signs of disease progression
Explore response rates across organs
A subgroup analysis of response at week 24
Explore response rates across organs
A subgroup analysis of response at week 24
See results for moderate vs severe disease
A subgroup analysis of response at week 24
See results for moderate vs severe disease
A subgroup analysis of response at week 24
Safety profile
Review the safety profile from the REACH3 trial
Safety profile
Review the safety profile from the REACH3 trial
Connect patients to benefits with IncyteCARES
Call 1-855-452-5234 (Monday through Friday, 8 AM to 8 PM ET) or visit hcp.IncyteCARES.com.
*Efficacy data from Jakafi Prescribing Information.
†Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.4
‡The NCCN does not recommend one systemic agent as preferred over another in SR GVHD.4 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 19, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
BAT=best available therapy; cGVHD=chronic graft-versus-host disease; CI=confidence interval; HCT=hematopoietic cell transplantation; NCCN=National Comprehensive Cancer Network® (NCCN®); OR=odds ratio; ORR=overall response rate; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid refractory.
References: 1. Lueck C, Tzalavras A, Wohlfarth P, et al. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2023;58(3):303-310. 2. Zeiser R, Polverelli N, Ram R, et al; for the REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228-238. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2033122. 3. Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 19, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.